Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have received a consensus recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $43.33.

A number of brokerages have recently commented on BCAX. Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 target price on the stock. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Morgan Stanley started coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price for the company. TD Cowen assumed coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating on the stock. Finally, Cantor Fitzgerald began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating for the company.

Bicara Therapeutics Price Performance

BCAX opened at $20.79 on Friday. The firm’s fifty day simple moving average is $22.31. Bicara Therapeutics has a 52-week low of $17.41 and a 52-week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, research analysts forecast that Bicara Therapeutics will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Bicara Therapeutics

In other news, Director Ra Capital Management, L.P. bought 1,833,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was bought at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the transaction, the director now directly owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. The trade was a 74.20 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder James E. Flynn purchased 70,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the acquisition, the insider now directly owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. The trade was a 8.46 % increase in their position. The disclosure for this purchase can be found here.

Institutional Trading of Bicara Therapeutics

Institutional investors have recently made changes to their positions in the business. Cinctive Capital Management LP acquired a new position in Bicara Therapeutics during the 3rd quarter valued at about $229,000. Barclays PLC acquired a new position in shares of Bicara Therapeutics during the third quarter valued at about $255,000. Jane Street Group LLC acquired a new position in shares of Bicara Therapeutics during the third quarter valued at about $309,000. Teachers Retirement System of The State of Kentucky purchased a new position in shares of Bicara Therapeutics in the 3rd quarter valued at approximately $358,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Bicara Therapeutics during the 3rd quarter valued at approximately $462,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.